An Unusual Case of Pancreatic Adenocarcinoma Metastasis to the Trapezium Bone.
1/5 보강
Pancreatic adenocarcinoma is an aggressive malignancy that accounts for over 90% of pancreatic cancers.
APA
Gordon KS, Nagi T, et al. (2025). An Unusual Case of Pancreatic Adenocarcinoma Metastasis to the Trapezium Bone.. Journal of medical cases, 16(4), 131-134. https://doi.org/10.14740/jmc4282
MLA
Gordon KS, et al.. "An Unusual Case of Pancreatic Adenocarcinoma Metastasis to the Trapezium Bone.." Journal of medical cases, vol. 16, no. 4, 2025, pp. 131-134.
PMID
40322627 ↗
DOI
10.14740/jmc4282
Abstract 한글 요약
Pancreatic adenocarcinoma is an aggressive malignancy that accounts for over 90% of pancreatic cancers. It is associated with a poor prognosis and a 5-year survival rate of less than 10%. In 2023, there were an estimated 64,050 new cases of pancreatic cancer and 50,550 related deaths. Common sites of metastasis include the liver, lungs, lymph nodes, and peritoneal cavity. While bone metastases can occur, metastatic disease involving the bones of the hand is exceedingly rare. In this report, we present a case of metastatic pancreatic cancer involving the trapezium bone of the hand, along with a review of the literature.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Metastatic Pancreatic Adenocarcinoma with Germline BLM and Somatic ATM Mutations: A Case Report and Review of DNA Damage Response.
- Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.
- AMIGO2 as a Novel Biomarker Predicting Poor Prognosis and Associated with Adhesion-Driven Metastasis in Pancreatic Adenocarcinoma.
- AC005034.3/hsa-miR-126-5p/EIF3H axis: bioinformatics analysis, expression validation, and association with prognosis and immunosuppressive microenvironment in pancreatic adenocarcinoma.
- Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy.
- CT imaging findings following treatment with combination SBRT and chemotherapy versus stand-alone chemotherapy for locally advanced pancreatic adenocarcinoma.